Our Technology
Thetis has developed proprietary technology called HEALER to enable development of Resolvins as stable, small molecule drugs with composition of matter patent protection.
HEALER = High Efficiency Amino Lipid Enabled Release
Resolvins in their native state as lipids or formulated as conventional pharmaceutical salts are unstable, oily materials that are difficult to formulate and lack intellectual property protection.
Our HEALER technology overcomes these fundamental obstacles, transforming Resolvins into new molecules with vastly improved physical and chemical properties to enable development as stable drugs for oral, parenteral, inhalable, sublingual or topical administration.
Our lead compound, TP-317, is Resolvin E1 magnesium di-lysinate, a novel small molecule with composition of matter and method of use (MOU) patents in the United States, Europe, Japan, China, Korea, and Australia (and pending in Canada). Additional MOU and formulation patents are pending worldwide. As a new chemical entity (NCE), TP-317 is expected to benefit from NCE data exclusivity in the U.S. and Europe.